 The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Incs NASDAQ: LTRN LP-184 for Atypical Teratoid Rhabdoid Tumor ATRT, a form of cancer of the Central Nervous System. LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways. 